Melanoma Institute Australia
Welcome,         Profile    Billing    Logout  
 31 Trials 
25 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thompson, John
NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Recruiting
2
246
US
Active Comparator CT1812, Placebo Comparator
Cognition Therapeutics
Age-Related Macular Degeneration
07/27
08/27
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
Gonzalez, Maria Jesus
ASPIRE, NCT04118088: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Active, not recruiting
4
50
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
03/26
03/26
NCT05357989: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Active, not recruiting
2
797
Canada, US, RoW
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
09/24
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Recruiting
2
218
Europe, RoW
Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy
Melanoma Institute Australia, Bristol-Myers Squibb
Melanoma Stage Iv
08/24
08/25
ADEPPT, NCT05673187 / 2022-002736-31: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

Recruiting
2
68
Europe
Adagrasib
ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc.
NSCLC Stage IV, KRAS P.G12C
10/25
03/26
STX-001-01, NCT06249048: Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Recruiting
1/2
108
US, RoW
STX-001, Keytruda®, Pembrolizumab
Strand Therapeutics Inc.
Advanced Solid Tumor
05/27
11/28
NCT04232696: Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)

Active, not recruiting
N/A
242
Europe, US
Neuspera Implantable Sacral Nerve Stimulation System
Neuspera Medical, Inc.
Urinary Urgency Incontinence
07/24
12/26
Long, Georgina
NADINA, NCT04949113 / 2021-001492-16: Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruiting
3
423
Europe, US, RoW
Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo
The Netherlands Cancer Institute, Bristol-Myers Squibb
Malignant Melanoma Stage III
01/24
12/28
ABC, NCT02374242 / ACTRN12614001315606: Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Active, not recruiting
2
76
RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016
Melanoma Institute Australia, Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb
Melanoma, Brain Metastases
09/17
12/28
NeoTrio, NCT02858921: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Active, not recruiting
2
60
RoW
Dabrafenib, Tafinlar, Trametinib, Mekinist, Pembrolizumab, Keytruda
Melanoma Institute Australia, Merck Sharp & Dohme LLC, Novartis
Melanoma
01/22
11/24
Neo PeLe, NCT04207086: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Active, not recruiting
2
21
RoW
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Melanoma Institute Australia, Merck Sharp & Dohme LLC
Melanoma Stage III
01/23
01/33
Neo-MCC, NCT06151236: Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Recruiting
2
20
RoW
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag
Melanoma Institute Australia, Bristol-Myers Squibb
Merkel Cell Carcinoma
04/26
04/34
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Recruiting
2
218
Europe, RoW
Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy
Melanoma Institute Australia, Bristol-Myers Squibb
Melanoma Stage Iv
08/24
08/25
Neo ReNi II, NCT05418972: A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

Recruiting
2
20
RoW
Relatlimab and nivolumab fixed dose combination (FDC), Opdualag
Melanoma Institute Australia, Bristol-Myers Squibb
Stage II Melanoma
12/24
12/34
KEYNOTE-D36, NCT05309421: A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Recruiting
2
90
RoW
EVX-01, Pembrolizumab 25 MG/ML, Keytruda
Evaxion Biotech A/S, Merck Sharp & Dohme LLC
Melanoma Stage III, Melanoma Stage IV
06/25
07/25
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Recruiting
2
60
Europe, US, RoW
IO102-IO103, Pembrolizumab KEYTRUDA®
IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC
Melanoma, Squamous Cell Carcinoma of Head and Neck
04/25
01/27
Neo PeLeMM, NCT05545969: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma

Withdrawn
2
44
RoW
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Melanoma Institute Australia, Merck Sharp & Dohme LLC
Mucosal Melanoma
05/26
05/36
MatchMel, NCT02645149: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Recruiting
2
1000
RoW
Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study
Melanoma Institute Australia, Novartis
Melanoma
07/27
12/28
NCT04834973: A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Terminated
1/2
3
RoW
tigilanol tiglate, EBC-46, pembrolizumab, Keytruda
QBiotics Group Limited, Merck Sharp & Dohme LLC
Melanoma
07/22
07/22
Menzies, Alexander
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Recruiting
2
218
Europe, RoW
Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy
Melanoma Institute Australia, Bristol-Myers Squibb
Melanoma Stage Iv
08/24
08/25
Lee, Jenny
Keynote- PNC-34, NCT04811027: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Checkmark Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC
Oct 2021 - Oct 2021: Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC
Active, not recruiting
2
171
Europe, US, RoW
Eftilagimod alpha, IMP321, Efti, Eftilagimod alfa, Pembrolizumab, Keytruda, MK-3475
Immutep S.A.S., Merck Sharp & Dohme LLC
HNSCC
03/24
03/25
DESQUAMATE, NCT05025813: Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

Recruiting
2
27
RoW
Pembrolizumab, External Beam Radiation Therapy, Radical Neck Dissection
Queensland Health, Merck Sharp & Dohme LLC
Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer
06/25
06/27
Long, Georgianna
No trials found
Salatino, Natalie
No trials found

Download Options